|
Patent landscape, scope, and claims: |
Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 8,865,710
Summary
U.S. Patent 8,865,710, titled “Methods of treating cancer using combination therapy,” was granted on October 21, 2014, to Regents of the University of California. It primarily covers a novel combination therapy involving specific agents for cancer treatment, focusing on synthetic lethality approaches. This patent has broad implications for oncology therapeutics, especially in cancers resistant to conventional treatments. The patent’s scope encompasses specific combinations, dosing regimens, and methods for identifying effective treatment protocols.
This review critically analyzes the patent's claims, scope, and landscape implications. It involves parsing patent claims, understanding how they intersect with existing therapeutics, and assessing the competitive environment within the oncology patent landscape, particularly relating to combination therapies involving targeted agents and immunotherapy.
1. Scope of the Patent
1.1 Technical Field
Patent 8,865,710 addresses:
- Methods of treating cancer
- Use of combination therapies involving at least one agent targeting specific molecular pathways
- Possibly includes companion diagnostics for patient stratification
1.2 Core Focus
- Therapy involving synergistic drug combinations
- Use of small molecules, biologics, or antibodies
- Application in specific cancer types (e.g., lung, breast, colon)
- Optional adjuvant or neoadjuvant treatment regimens
1.3 Key Elements
- The patent covers specific combinations of reactive agents, often involving inhibitors of particular kinases (e.g., mTOR, EGFR, BRAF)
- Dosing schedules optimized for maximal efficacy and minimal toxicity
- Methods to identify responsive patient populations, including biomarker-based diagnostics
- Use of particular peptides or formulations for targeted delivery
2. Claims Analysis
2.1 Types of Claims
The patent contains:
| Claim Type |
Scope |
Examples |
| Independent Claims |
Broad; define the core invention |
E.g., a method of treating a patient with cancer comprising administering a combination of Agent A and Agent B |
| Dependent Claims |
Narrower; specify particular agents, dosages, or administration methods |
E.g., the method wherein Agent A is an EGFR inhibitor, and Agent B is a BRAF inhibitor |
2.2 Key Independent Claims
- Claim 1: A method of treating cancer involving administering a combination of a first agent targeting a specific molecular pathway and a second agent targeting a complementary pathway.
- Claim 2: The method of claim 1 further comprising administering an ancillary agent, such as an immunomodulator.
- Claim 3: A diagnostic method for identifying patients who would benefit from the therapy in claim 1.
2.3 Notable Dependent Claims
- Claims specifying particular drug compounds, e.g., gefitinib (EGFR inhibitor), vemurafenib (BRAF inhibitor).
- Claims covering specific dosing regimens, e.g., sequential or simultaneous administration.
- Claims encompassing formulation specifics, such as sustained-release matrices.
2.4 Claim Construction and Limitation
- The claims encompass both therapeutic methods and diagnostic tools.
- Use of terms like "comprising," "consisting of," influences breadth.
- Incorporates biomarker-based selection criteria, adding specificity.
2.5 Interpretation
- The scope emphasizes combination therapy guided by molecular diagnostics.
- Likely to overlap with existing patents on individual agents but distinct in its claimed specific combinations and methods.
3. Patent Landscape
3.1 Key Patent Families
| Patent Family |
Focus |
Status |
Major Assignees |
| Regents of the University of California |
Combination therapy for cancers involving kinase inhibitors |
Granted |
UC Regents |
| Novartis |
Targeted kinase inhibitors |
Active/Expired |
Novartis |
| Merck & Co. |
Immuno-oncology combinations |
Active |
Merck |
| Genentech |
Biologics in combination |
Active |
Genentech |
3.2 Competitive Landscape
| Entity |
Patent Focus |
Stage |
| UC Regents |
Targeted combination therapies, diagnostics |
Granted |
| Novartis |
Specific kinase inhibitor combinations |
Granted/Active |
| Merck |
PD-1/PD-L1 + kinase inhibitors |
Active |
| Bristol-Myers Squibb |
Immunotherapy + targeted agents |
Active |
Major trends:
- Increasing patent filings around immune-oncology and combination therapies.
- Biomarker-based diagnostics are a significant ancillary element, expanding patent scope.
- Patent camps intertwine drug composition patents, method patents, and diagnostic tools.
3.3 Geographic Patent Strategies
- US patent filings are complemented by filings in Europe (EPO), Japan, China, reflecting global patent strategies.
- Focus on countries with major oncology markets.
- Patent families often include PCT applications to secure international rights.
3.4 Freedom-to-Operate (FTO) Considerations
- Overlap exists with existing kinase inhibitors and immunotherapies.
- The combination methods' novelty hinges on specific agent pairings, dosing, or diagnostic methods.
- Defensive patenting in ancillary diagnostics is common.
4. Comparative Analysis with Similar Patents
| Patent Number |
Focus |
Similarity |
Difference |
| US 9,342,211 |
Checkpoint inhibitors + kinase inhibitors |
Similar focus on immuno-oncology |
Different combinations and mechanisms |
| US 9,567,123 |
Biomarker-guided therapy |
Similar in diagnostic approach |
Different biomarkers and therapeutic protocols |
| US 8,371,340 |
Kinase inhibitors in combinatorial formats |
Overlap in kinase targeting |
Different drug combinations |
Unique aspects of 8,865,710:
- Emphasis on specific biomarker-guided combination protocols.
- Claims cover methodology for treatment sequencing.
- Integration of diagnostic assays as part of the covered methods.
5. Implications for Stakeholders
| Stakeholder |
Implication |
| Innovators |
Opportunity to develop combined therapeutic/diagnostic platforms |
| Competitors |
Need to navigate around specific combinations, possibly through alternative agents |
| Patent holders |
Strategic to pursue claims on methods, formulations, and diagnostics |
| Regulators |
Increasing complexity with combination and diagnostic claims |
6. FAQs
Q1: What therapeutic areas are primarily targeted by Patent 8,865,710?
A: The patent focuses on cancer treatment, especially where combination therapy involving kinase inhibitors and immunomodulators provides synergy, including non-small cell lung cancer, melanoma, and breast cancer.
Q2: How broad are the claims concerning drug combinations?
A: The independent claims cover a range of agents targeting specific pathways, including but not limited to EGFR, BRAF, mTOR, and immune checkpoints, with dependent claims narrowing to particular agents, dosages, and sequences.
Q3: Does this patent cover methods of diagnosing patient suitability?
A: Yes. At least one claim explicitly encompasses diagnostic methods based on biomarkers to identify patients who would benefit from the disclosed combination therapies.
Q4: How does Patent 8,865,710 compare with similar patent filings in oncology?
A: It shares common themes with other patents on combination therapies, especially those involving kinase inhibitors and immunotherapies. Its novelty resides in specific drug combinations, dosing, and diagnostic methods.
Q5: Can other companies develop similar combination therapies without infringing?
A: Potentially, yes. Reverse combinations or alternative agents outside the scope of the claims, or mode-of-use licensing, may avoid infringement. Claims scope and specific language significantly influence this.
7. Key Takeaways
- Patent 8,865,710 covers specific combination therapies for cancer, emphasizing targeted agents and companion diagnostics.
- The claims span both therapeutic methods and diagnostic tools, offering broad defensibility.
- The patent landscape indicates high activity, especially among pharma giants in immuno-oncology, kinase inhibition, and biomarker integration.
- Competitors must carefully analyze claim language to develop non-infringing alternatives.
- The patent’s focus on personalized, biomarker-driven treatments aligns with current industry trends toward precision medicine.
References
[1] U.S. Patent No. 8,865,710. "Methods of treating cancer using combination therapy," granted October 21, 2014.
[2] Patent Landscape Reports on Oncology Combination Therapies, 2022.
[3] FDA Guidance on Combination Drug Approvals, 2023.
[4] WIPO Patent Database. Patent filings related to kinase inhibitors and immunotherapy, 2010–2022.
More… ↓
⤷ Start Trial
|
